Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Guillermo Garcia-Manero, MD, Maciej Kaźmierczak, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Adriano Venditti, Silvia Mappa, MD, Riccardo Spezia, Lionel Ades, MD PhD

Blood (2019) 134 (Supplement_1): 2652.

https://doi.org/10.1182/blood-2019-125924

Published: 2019

Journal Articles

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Michael K Keng, MD, Samer K. Khaled, MD, Brenda Cooper, MD, Erica D. Warlick, MD, David Ramies, MD, Silvia Mappa, MD, Ehab L. Atallah, MD

Blood (2018) 132 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2018-99-112741

Published: 2018

Journal Articles

Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma

Martin Dreyling, David Cunningham, FMedSci, Krimo Bouabdallah, MD, Sarit Assouline, MD MSc, Eric Van den Neste, Umberto Vitolo, MD, Marius Giurescu, MD PhD, Silvia Mappa, MD, Julia Grunert, Barrett H. Childs, MD, Franck Morschhauser

Blood (2014) 124 (21): 1701.

https://doi.org/10.1182/blood.V124.21.1701.1701

Published: 2014

Journal Articles

Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma

Martin Dreyling, Franck Morschhauser, MD, PhD, Dominique Bron, MD, PhD, Krimo Bouabdallah, MD, Umberto Vitolo, MD, Kim Linton, Eric Van Den Neste, MD, PhD, Silvia Mappa, MD, Marius Giurescu, MD, PhD, Barrett H. Childs, MD, Pier Luigi Zinzani, MD

Blood (2013) 122 (21): 87.

https://doi.org/10.1182/blood.V122.21.87.87

Published: 2013

Journal Articles

Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL)

Marta Bruno Ventre, MD, Giovanni Donadoni, MD, Alessandro Re, MD, Michele Spina, MD, Chiara Cattaneo, Luca Fumagalli, MD, Silvia Mappa, MD, Silvia Govi, MD, Giuseppe Rossi, MD, Umberto Tirelli, MD, Andrés JM Ferreri, MD

Blood (2011) 118 (21): 2692.

https://doi.org/10.1182/blood.V118.21.2692.2692

Published: 2011

Journal Articles

Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment (the IELSG#27 TRIAL)

Silvia Govi, MD, Riccardo Dolcetti, MD, Maurilio Ponzoni, MD, Elisa Pasini, RF, Silvia Mappa, MD, Marta Bruno Ventre, MD, Claudio Doglioni, MD, Francesco Bertoni, MD, Francesco Zaja, MD, Carlos Montalban, MD, PhD, Caterina Stelitano, MD, Maria Elena Cabrera, MD, Franco Cavalli, MD, Emanuele Zucca, MD, Andrés J.M. Ferreri, MD

Blood (2011) 118 (21): 267.

https://doi.org/10.1182/blood.V118.21.267.267

Published: 2011

Journal Articles

Dose-Dense CHOP Plus Rituximab (R-CHOP14) Seems To Overcome, in Large B Cell Lymphoma, the Negative Prognostic Significance of B Cell Origin.

Luigi Rigacci, MD, Luca Nassi, MD, Simonetta di Lollo, MD, Benedetta Puccini, MD, Morena Doria, MD, Silvia Mappa, MD, Gloria Capaccioli, Renato Alterini, MD, Valentina Carrai, MD, Alberto Bosi, MD

Blood (2007) 110 (11): 4401.

https://doi.org/10.1182/blood.V110.11.4401.4401

Published: 2007

Journal Articles

Liposomal Doxorubicin in the Treatment of Elderly, Cardiopatic, or Pretreated Patients with Aggressive Lymphomas: Comparison with an Historical Series.

Luigi Rigacci, MD, Silvia Mappa, MD, Luca Nassi, MD, Renato Alterini, MD, Valentina Carrai, MD, Franco Bernardi, MD, Alberto Bosi, MD

Blood (2006) 108 (11): 4685.

https://doi.org/10.1182/blood.V108.11.4685.4685

Published: 2006

Journal Articles

First Line Treatment with Rituximab and Chlorambucil in the Treatment of Ocular Adnexal Lymphomas.

Luigi Rigacci, MD, Marco Puccioni, MD, Luca Nassi, MD, Silvia Mappa, MD, Cinzia Mazzini, MD, Renato Alterini, MD, Valentina Carrai, MD, Ennio Polito, MD, Alberto Bosi, MD

Blood (2006) 108 (11): 4712.

https://doi.org/10.1182/blood.V108.11.4712.4712

Published: 2006

Journal Articles

Time- and Dose-Response Relationships of Imatinib Mesylate (Glivec) Therapy for Chronic Hypereosinophilic Syndromes.

Renato Bassan, MD, Sara Acerboni, BSc, Silvia Mappa, MD, Piera Viero, MD, Federica Delaini, BSc, Giuseppe Rossi, Valentina Rossi, A. Vannucchi, MD, Eros Di Bona, MD, Emanuela Ruggeri, Anna Salvi, Ursula Giussani, BSc, Francesca Rancati, MD, Tamara Intermesoli, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD

Blood (2005) 106 (11): 2596.

https://doi.org/10.1182/blood.V106.11.2596.2596

Published: 2005

NARROW

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma

Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma

Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL)

Dose-Dense CHOP Plus Rituximab (R-CHOP14) Seems To Overcome, in Large B Cell Lymphoma, the Negative Prognostic Significance of B Cell Origin.

Liposomal Doxorubicin in the Treatment of Elderly, Cardiopatic, or Pretreated Patients with Aggressive Lymphomas: Comparison with an Historical Series.

First Line Treatment with Rituximab and Chlorambucil in the Treatment of Ocular Adnexal Lymphomas.

Time- and Dose-Response Relationships of Imatinib Mesylate (Glivec) Therapy for Chronic Hypereosinophilic Syndromes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only